TATE: Near-Term Headwinds Will Present Attractive Recovery Opportunity Ahead

Tate & Lyle's consensus price target has been reduced significantly, with analysts citing cautious fiscal guidance and industry contract headwinds as key factors in the revised outlook. The price target has shifted from approximately £6.50 down to a range between £4.30 and £5.40 per share.

Shared on 31 Oct 25

Fair value Decreased 4.40%

Tate & Lyle's analyst price target has been reduced from approximately £5.53 to £5.28 per share, as analysts cite concerns over the company's revised guidance and increased risks to its medium-term outlook. Analyst Commentary Recent research notes show a range of perspectives regarding Tate & Lyle's performance and future prospects, highlighting both potential strengths and emerging risks for the company.

Shared on 17 Oct 25

Fair value Decreased 12%

Tate & Lyle's analyst price target has been revised downward by approximately 12%, from £6.26 to £5.53 per share. Analysts cite growing concerns over softer demand trends and pressure on future earnings growth.

Shared on 03 Oct 25

Fair value Decreased 12%

Tate & Lyle’s analyst price target has been revised downward by analysts, dropping sharply from approximately £7.09 to £6.26 per share. Recent research highlights concerns about a softer revenue growth outlook and potential headwinds from contract renegotiations and product mix changes.

Shared on 17 Sep 25

Fair value Decreased 2.61%

The slight reduction in Tate & Lyle’s consensus price target reflects a modest decline in net profit margin, resulting in a new fair value of £7.09. What's in the News Tate & Lyle is showcasing health-focused ingredient innovations at the IFT FIRST Conference, including advancements in sugar reduction, fiber fortification, and novel textures.